A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart ...

Hyperkalemia is a potentially life-threatening side effect of RAASi use. Individuals with heart failure are particularly susceptible because heart failure itself can cause hyperkalemia. “Several ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

Hyperkalemia, an electrolyte disorder associated with kidney dysfunction, is relatively common among emergency department (ED) patients and can be life threatening, predominantly due to cardiac ...

Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure. Cardiorenal risks increase following discontinuation or downtitration of ...

Finerenone use in trial patients with HFpEF or HFmrEF increased hyperkalemia risk, especially in those with CKD. Finerenone use in patients with heart failure and preserved or mildly reduced ejection ...

The symptoms of hyperkalemia begin with muscle weakness. As serum potassium levels rise, symptoms progress to more significant muscle twitching, weakness, nausea, and cramping. [69] Cardiac conduction ...

Please provide your email address to receive an email when new articles are posted on . A potassium binder enabled more patients with heart failure to stay on ...

NEW YORK--(BUSINESS WIRE)--AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ Guard TM, an FDA Breakthrough Device ...